Purpose: To describe the requirements for managing IP at the clinical site
|
|
- Dustin Newman
- 6 years ago
- Views:
Transcription
1 Title: Investigational Product Management Topic: Management of IP Effective Date: March 16, 2016 Approved By: Rita Hanson, M.D. Senior VP/Chief Medical Officer Purpose: To describe the requirements for managing IP at the clinical site Scope: This procedure applies to IP used in any clinical trial/human research conducted by the Clinical Research Department at any Wheaton Franciscan Healthcare facility in Wisconsin or Iowa. Procedure: Study team members will comply with a site s specific IP management policy if there is an active policy at that site. If the active site policy does not include procedures in this policy, the study team will follow this policy to the extent that the procedure is not covered by the active site policy. IP management includes proper handling, storage, and disposition. Accountability The PI or designee must maintain appropriate records as follows: 1. Receipt of shipment(s) 2 Inventory at the site 3. Dispensation/use by each subject 4. Disposition return to sponsor or disposal. These records should include the following: a. Name of IP b. Dates c. Quantities d. Batch/serial numbers (or other identifying code) The PI or designee will not use IP past its expiration date (if applicable) and contact the study sponsor regarding any IP with imminent expiration dates. Storage Protocol defined storage of IP with respect to temperature, humidity, lighting, and other Standard Operating Procedures Version: February 2016 Page 1 of 12
2 environmental considerations will be followed. IP will be stored in a secure area with limited access, in accordance with applicable regulatory requirements. IP will be labeled in such a way that they are not dispensed to patients outside of the intended investigational protocol. Temperature logs will be maintained per the sponsor s protocol or authorization to use the site s temperature logs. Deviations from the storage temperature requirements for IP must be recorded and reported to the study sponsor. The affected IP will be quarantined until the study team receives instructions from the sponsor. Dispensation and Administration IP will be dispensed to subjects only by qualified investigators or qualified study team members. Drug, infant formula, food supplements or food fortifiers that are being studied will only be dispensed to the subject upon receipt of an authorized investigator s order. For NCI-sponsored Oncology trials, the pharmacist or coordinator will verify that the ordering investigator is part of the IRB-approved study team. The pharmacist or coordinator will also verify that the ordering investigator is registered and active with the NCI prior to filling an IP order by: 1. accessing and entering the last name and investigator ID number to confirm active registration, or 2. CTEP registration using ctepreghelp@ctep.nci.nih.gov. If the IP is not ordered by a NCI registered and active investigator, the order must be co-signed or re-ordered by an investigator who is actively registered. In the event the IP is not ordered by, or not co-signed by, a NCI-registered investigator, the IP should not be dispensed to the subject and a study coordinator should be notified. If more than one location will be used for IP storage or dispensation, the sponsor will be notified and the Form FDA 1572 or Investigator s Agreement should accordingly reflect all locations. The PI or designee will follow the clinical trial s randomization procedures, if any, and ensure that the code is broken only in accordance with the protocol. The PI or designee will follow the clinical trial s blinding procedures, if any. Any incidence of unblinding will be reported to the sponsor. The PI or designee will ensure that the IP is used only in accordance with the approved protocol. The PI or designee is responsible for educating each subject regarding the correct use of the IP as defined in the protocol. Standard Operating Procedures Version: February 2016 Page 2 of 12
3 Study team members will provide only IRB-approved patient education materials and/or IP administration information to subjects. The PI or designee will maintain prospective records of study materials returned by each subject. Compliance will be assessed by review of returned IP for each subject. Lost or unreturned IP will be documented in source documentation and in the IP accountability log(s). Controlled Substance If the IP is subject to the Controlled Substance Act, the PI or designee will take adequate precautions, including storage of the investigational drug in a double-locked, well-constructed cabinet or enclosure with limited access to prevent theft or diversion of the substance into illegal channels of distribution. Investigators or designees will comply with Drug Enforcement Agency (DEA) regulations in addition to the FDA regulations and will obtain DEA registration for the controlled substance(s), if required. IP Site Change If IP is transferred from one site to another, the PI or designee will record: 1. IP lot number (or other applicable study identifier) 2. Transfer date 3. Quantity transferred 4. Name of the person receiving the IP 5. If the IP is not transferred through a Wheaton pharmacy, document the name of the person transferring the IP. Disposition of IP At sponsor-authorized intervals throughout a clinical trial, and at the conclusion of a trial, the sponsor representative(s) will conduct final accountability and reconciliation prior to IP return and/or disposition if possible. Otherwise, IP will be returned to the sponsor or destroyed according to the sponsor s instructions. Should the sponsor not provide instructions for return and/or destruction, a study team member will follow the study site pharmacy s standard operating procedures for product destruction. Please see Pharmacy policy and Procedure for further description. Documentation All IP accountability must be accurately recorded and filed with other supporting documents in study binders. Study staff will document IP receipt, use, disposition, return, destruction and all other accountability procedures, as required by the FDA, on sponsor provided forms. If the sponsor does not provide forms for such documentation, study staff will use the logs provided in this SOP or similar documentation that has been approved by the sponsor. Standard Operating Procedures Version: February 2016 Page 3 of 12
4 Responsibility: The PI is ultimately responsible for all aspects of the clinical trial that she/he directs, including the management and accountability of IP. The PI is responsible for authorizing individuals who may prescribe and/or dispense IP as applicable. The PI may delegate some or all of their duties for IP management and accountability to qualified site personnel who act under his/her supervision. Regulations/Guidelines CFR Title 21; Record Keeping and Record Retention CFR Title Disposition of Unused Supply of Investigational Drug CFR Title Control of Investigational Drug CFR Title Investigator Record Keeping and Record Retention CFR Title Handling of Controlled Substances CFR Title , Subpart G - Reports and Record CFR Title Labeling of Investigational Devices CFR Title Records ICH GCP Consolidated Guideline - Part 4.6 Investigational Product ICH GCP Consolidated Guideline - Part 4.7 Randomization Procedures and Unblinding Version No. 1.0 New document created (3/2009) Revision Description 2.0 Revised 12/2015; Including title change from Investigational Agent Management to Investigational Product Management 3.0 Revised 2/2016 Standard Operating Procedures Version: February 2016 Page 4 of 12
5 Investigational Product (IP) Accountability Record Wheaton Franciscan Healthcare Investigational Product Accountability Name of Institution: Page No. : IP Name: Protocol No.: Protocol Title: Storage Area: Principal Investigator s Name: PI/Coordinator/Designee Signature and Date: Line No. Date Patient s Initials Patient s ID No. Lot, Serial, Model No. or Other Identifier Quantity Dispensed or Received Balance Forward Amount Unused or Expired Comment (e.g., dose, etc.) Recorder s Initials Balance Standard Operating Procedures Version: February 2016 Page 5 of 12
6 Storage and Access Plan for Investigational Products that are Controlled Substances Investigational Product: Sponsor: STUDY INFORMATION Protocol No.: Investigator: Site: Location of IP Storage STORAGE AND ACCESS PLAN Office address: Room: Type of cabinet/container for IP: Check to verify that IP cabinet/container is: securely locked substantially constructed List of all people who have access to the key (including PI, Wheaton Franciscan Healthcare associates, and others if applicable): Comments: Signature and date by the Director of Wheaton Franciscan Healthcare Research Department indicating that he/she has reviewed, verified, and endorsed the above plan: Director of WFH Research Department Date Signature and date by the PI or organizational official under whose controlled substance license the drug is shipped (if the latter, the person signing must be a licensed pharmacist who works for that organization) indicating that he/she has reviewed, verified, and endorsed the above plan: Principal Investigator or Licensed Pharmacist Date Standard Operating Procedures Version: February 2016 Page 6 of 12
7 IntraSite Transfer Investigational Product (IP) Form Wheaton Franciscan Healthcare Investigational Product Accountability INSTRUCTIONS FOR TRANSFERS: 1. Properly complete all sections 2. Type or print all information one transfer per page; one protocol per page 3. Enter signature of individual preparing IP and receiving IP 4. Pack the IP well to minimize breakage and leakage for transfers 5. All IPs must be transferred per sponsor specifications for handling/transport 6. Enclose the completed list with the IP IP Transferred From Name of Institution: Street Address City/State/Zip Code PI Name: IP Transferred To Name of Institution: Street Address City/State/Zip Code Protocol No.: Sponsor IP Name Quantity (include units) Lot/Serial No. or other Identifier Comments (dosage, etc.) Departure Date/Time: Departure Temp: Arrival Date/Time: Arrival Temp: Reason for transfer: Dispensing to active subject Return from subject : Additional Comments: If not transferring IP through a Wheaton pharmacy, document the name of the person transferring IP. Name: Title: LOCATION TRANSFERING IP: Signature/Printed Name Investigator or Preparer: Date: LOCATION RECEIVING IP: Signature/Printed Name Investigator or Receiver: Date: Title: Phone No.: Title: Phone No.: Standard Operating Procedures Version: February 2016 Page 7 of 12
8 Return Investigational Product (IP) to Sponsor Form Wheaton Franciscan Healthcare Investigational Product Accountability INSTRUCTIONS FOR RETURNS: 1. Properly complete all sections 2. Type or print all information one item, lot, or protocol per line 3. PI or individual preparing this form signs this form 4. Pack the IP well to minimize breakage and leakage 5. All IP may be returned via room temperature shipment unless otherwise specified, but must be transferred per sponsor specifications for handling/transport 6. Enclose this completed form with the IP Site Name: Site Address: Check here if a returned receipt/confirmation should be mailed to the above address. Otherwise provide fax number for return receipt: Protocol Name/No.: Site No: PI: Airbill No.: Address of Location Receiving IP: IP Name Quantity (include units) Lot/ Serial No. (or other ID) Strength, Dose or Description Signature and Title of Person Preparing IP for Return Signature and Title of Person Receiving IP Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired Reason for return: All subjects off treatment IP expired LOCATION RETURNING IP LOCATION RECEIVING IP Signature of PI or Preparer: Phone No.: Signature of Receiver Return receipt sent to site by mail or fax. Title: Date Returned: Title: Date received: Standard Operating Procedures Version: February 2016 Page 8 of 12
9 Investigational Product (IP) Destruction Record Wheaton Franciscan Healthcare Investigational Product Accountability Name of Institution: Page No. Protocol No. IP Name: Protocol Title: Principal Investigator Name: Personnel Authorizing Destruction/Return: Destruction Location/Return Destination: PI/Coordinator/Designee Sign and Date: Line No. 1. Date Dose, Bottle or Lot # Quantity Destroyed/ Returned Balance Forward Balance Recorder s Initials Standard Operating Procedures Version: February 2016 Page 9 of 12
10 TEMPERATURE MONITORING LOG IRB #: Study Name: Location of measurement instrument: Standard Operating Procedures Version: February 2016 Page 10 of 12
11 TEMPERATURE MONITORING LOG IRB #: Study Name: Location of measurement instrument: o F o C Temperature Date Initial Temperature Date Initial Standard Operating Procedures Version: February 2016 Page 11 of 12
12 Page left intentially blank. Standard Operating Procedures Version: February 2016 Page 12 of 12
Chapter 10: Regulatory Documentation
Table of Contents Chapter 10: Regulatory Documentation... 10-1 10.1 Regulatory Requirements:... 10-1 10.2 Ongoing Regulatory Documents:... 10-4 10.3 After study completion or termination of the trial...
More informationTexas A&M University Controlled Substances Guidelines Training Module. September 2017
Texas A&M University Controlled Substances Guidelines Training Module September 2017 Applicability Guidelines for the purchase, storage, use, and disposal of controlled substances used in research and
More informationUse of Controlled Substances in Research
Use of Controlled Substances in Research A Tutorial on Regulatory Requirements and the Emory University Policy 7.25 Research Use of Controlled Substances Emory University, Office of Compliance Tutorial
More informationWayne State University
Wayne State University Office of Environmental Health & Safety Controlled Substances Program Why is Wayne State doing this? In 2011, a survey of our laboratories revealed that some were not adhering to
More informationGUIDELINES FOR THE USE OF DEA CONTROLLED SUBSTANCES
GUIDELINES FOR THE USE OF DEA CONTROLLED SUBSTANCES The Drug Enforcement Agency has specific registration and management guidelines for researchers using controlled substances. This document provides a
More informationControlled Substances
45.75.1 POLICY This policy addresses obtaining, using, storing, recordkeeping, dispensing, and disposing of controlled substances at WSU. This policy provides information and procedures to enable individuals
More informationControlled Substance Training Manual
Controlled Substance Training Manual Last updated Aug2018 Table of Contents I. Purpose... 3 II. Responsibilities... 3 III. DEA Registration... 3 IV. Storage... 4 V. Handling and Transport... 4 VI. Recordkeeping...
More informationInformed Consent and the Consent Form
Informed Consent and the Consent Form What is informed consent? What does the process look like? Who can obtain consent? Where can I find more information? Consent Form Informed Consent They are NOT the
More informationRegistration and Credential Repository (RCR) Update and Demo
Registration and Credential Repository (RCR) Update and Demo Matthew Boron, RPh PMB, CTEP, NCI November 2-3, 2017 Goals and Objectives Describe why the Registration and Credential Repository was implemented
More informationELECTRONIC SITE DELEGATION LOG (esdl) USER MANUAL
Version 1.0 24May16 ELECTRONIC SITE DELEGATION LOG (esdl) USER MANUAL - Table of Contents - 1. INTRODUCTION... 3 Background... 3 Purpose of the Site Delegation Log... 3 TNCC Contacts... 3 2. SYSTEM REQUIREMENTS...
More informationThe Lilly Safety Mailing Process
The Lilly Safety Mailing Process 1 After this presentation you will be able to: Define Safety Mailings and the type of adverse events that trigger safety mailings. Define Principal Investigator (PI) and
More informationGeneral Guidance for Maintaining a Regulatory Binder
General Guidance for Maintaining a Regulatory Binder Study documentation should be well organized, providing a complete and thorough history from protocol development to study completion. Maintaining a
More informationFederal Regulations regarding DEA Form 222
Federal Regulations regarding DEA Form 222 DEA Form 222, which is used for ordering schedule II narcotics, is discussed under Title 21 of the Code of Federal Regulations. To obtain DEA Form 222, the medical
More informationREGULATORY REQUIREMENTS DEA LICENSED PHYSICIANS FOR. Pierce County EMS Meeting January 4, 2012
REGULATORY REQUIREMENTS FOR DEA LICENSED PHYSICIANS Pierce County EMS Meeting January 4, 2012 Ruth Carter Group Supervisor Seattle Field Division Drug Enforcement Administration OFFICE OF DIVERSION CONTROL
More informationControlled Substances in Research DEA Audit Preparation Checklist
Does the faculty member possess a current State of Georgia controlled substance research license or GA practitioner controlled substance license? Is the Georgia license present on site or readily retrievable?
More informationFederal Regulations regarding DEA Form 222
Federal Regulations regarding DEA Form 222 DEA Form 222, which is used for ordering schedule II narcotics, is discussed under Title 21 of the Code of Federal Regulations. To obtain DEA Form 222, the medical
More informationUNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS April 3, 2017 Bernadette Mahan, DI Drew Oesterle, DI DEA Denver The DEA Researcher A Review of Federal Rules and Regulations 3 Goals and Objectives What is
More informationRegistration and Credential Repository (RCR) Donna A Shriner, PharmD, MPH
Registration and Credential Repository (RCR) Donna A Shriner, PharmD, MPH April 21, 2017 Introduction The Registration and Credential Repository (RCR) will: Provide a self-service online person registration
More informationDEA Rule Changes: Impact on Industry Disposal Practices
DEA Rule Changes: Impact on Industry Disposal Practices Charlotte A. Smith, R. Ph., M.S. Senior Regulatory Advisor PharmEcology Services WM Healthcare Solutions, Inc. Practice Greenhealth October 15, 2014
More informationSITE FILE MANAGEMENT
SITE FILE MANAGEMENT STANDARD OPERATING PROCEDURE NO SOP 08 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES: To describe the procedure for the maintenance of essential documents
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer for Human Subject Research Compliance (HSRC) External
More informationDEA In a Community Pharmacy Part 1 By Bruce R. Siecker, Ph.D., R.Ph.
DEA In a Community Pharmacy Part 1 By Bruce R. Siecker, Ph.D., R.Ph. Bruce Siecker is president of Paradigm Research & Advisory Services, Inc. based in Stone Ridge, Virginia. He trains, writes, consults,
More informationSOP-QA-32 V2. Document History Version Description of update Date Effective 1 Change of number for Q-Pulse
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Gary Cooper, Named Archivist QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approved by QA: N/A Document
More informationORA HIPAA Security. All Affiliate Research Policy Subject: HIPAA Security File Under: For Researchers
All Affiliate Research Policy Subject: HIPAA File Under: For Researchers ORA HIPAA Issuing Department: Office of Research Administration Original Policy Date Page 1 of 5 Approved by: May 9,2005 Revision
More informationStandard Operating Procedure Clinical Data Management
P-CTU-010 Standard Operating Procedure Topic area: Data Management and Statistics Based on SCTO Matrix: Not applicable Identification number: P-CTU-010 Version: /- Valid from: 01.06.2014 Review and Approval
More informationQP Current Practices, Challenges and Mysteries. Caitriona Lenagh 16 March 2012
QP Current Practices, Challenges and Mysteries Caitriona Lenagh 16 March 2012 Agenda QP Roles and Responsibilities QP Current Practices Supply Chain Verification Study Specific Information Lot Specific
More informationSignature Practices and Technologies for TMF An Industry Overview. Kathie Clark Wingspan Technology Vice President Product Management
Signature Practices and Technologies for TMF An Industry Overview Kathie Clark Wingspan Technology Vice President Product Management 1 Agenda Review of Guidance and Regulations Research Approach Results
More informationPDMP User s Guide. Oregon Health Authority Prescription Drug Monitoring Program
Oregon Health Authority Prescription Drug Monitoring Program March 2014 Contents Contents 1 Document Overview... 1 Purpose and Contents... 1 RxSentry Update... 1 2 System Overview... 3 About the RxSentry
More informationSparta Systems TrackWise Digital Solution
Systems TrackWise Digital Solution 21 CFR Part 11 and Annex 11 Assessment February 2018 Systems TrackWise Digital Solution Introduction The purpose of this document is to outline the roles and responsibilities
More informationVersion Control of Study Specific Documents
SOP Title Version Control of Study Specific Documents SOP No. SOP 10 Author Consulted Departments Lead Manager Sign and Print Name Julia Farmery Revision V2.0: Sarah Fahy Lincolnshire Clinical Research
More informationInformation Security Policy
April 2016 Table of Contents PURPOSE AND SCOPE 5 I. CONFIDENTIAL INFORMATION 5 II. SCOPE 6 ORGANIZATION OF INFORMATION SECURITY 6 I. RESPONSIBILITY FOR INFORMATION SECURITY 6 II. COMMUNICATIONS REGARDING
More informationStandard Operating Procedure. Data Management. Adapted with the kind permission of University Hospitals Bristol NHS Foundation Trust
Data Management REFERENCE: VERSION NUMBER: 2.1 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager; Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director
More informationNew York Department of Financial Services Cybersecurity Regulation Compliance and Certification Deadlines
New York Department of Financial Services Cybersecurity Regulation Compliance and Certification Deadlines New York Department of Financial Services ( DFS ) Regulation 23 NYCRR 500 requires that entities
More informationSecurity and Privacy Breach Notification
Security and Privacy Breach Notification Version Approval Date Owner 1.1 May 17, 2017 Privacy Officer 1. Purpose To ensure that the HealthShare Exchange of Southeastern Pennsylvania, Inc. (HSX) maintains
More informationExamining Rescue Studies
White Paper Examining Rescue Studies Introduction The purpose of this White Paper is to define a Rescue Study, outline the basic assumptions, including risks, in setting up such a trial based on DATATRAK
More informationStandard Operating Procedure. SOP full title: Sponsor processes for reporting Suspected Unexpected Serious Adverse Reactions
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-03-003 Sponsor processes for reporting Suspected Unexpected Serious Adverse Reactions SOP effective: 23/05/2017 Review date: 23/05/2019
More informationCancer Clinical Trials Centre Standard Operating Procedure
Controlled Document - do not download/save/print/photocopy Cancer Clinical Trials Centre Standard Operating Procedure SOP No.: 17 Title: Archiving Current Version No.: 3.3 Reviewed & Endorsed by STH Research:
More informationThe No Fear DEA Audit
U.S. Drug Enforcement Administration Albuquerque District Office The No Fear DEA Audit Is there such a thing?!? Hopefully you will think so after this presentation! Shirley J. Scott Diversion Investigator
More informationJRO RMG RSS SOP 12. Standard Operating Procedure (SOP) for Study Closedown and Archiving
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Tel No. 0845 1555 000 Web-sites: www.uclh.nhs.uk; www.ucl.ac.uk/jro Postal Address: UCL, Gower Street
More informationOffice of Human Research
Office of Human Research JeffTrial End-User Training Document Regulatory Coordinator Training for Non-Oncology personnel Office of Human Research 8/16/2013 Ver. 1.0 Contents The REG Role: Completing Basic
More informationSPRING-FORD AREA SCHOOL DISTRICT
No. 801.1 SPRING-FORD AREA SCHOOL DISTRICT SECTION: TITLE: OPERATIONS ELECTRONIC RECORDS RETENTION ADOPTED: January 25, 2010 REVISED: October 24, 2011 801.1. ELECTRONIC RECORDS RETENTION 1. Purpose In
More informationW-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 January 2011 Part 1--Structure & Process of Controlled Substance Distribution 33rd Year HAVE YOU RECEIVED
More informationThis document applies to the use of controlled substances in research laboratories at the University.
1.0 PURPOSE Controlled Substance Program This procedure is to provide guidance and resource information for University faculty and staff who utilize controlled substances in teaching and research. This
More informationTraining Guide for Arkansas Law Enforcement Officers and Licensing Board Representatives
Training Guide for Arkansas Law Enforcement Officers and Licensing Board Representatives Arkansas Department of Health Prescription Monitoring Program March 2016 Contents Contents 1 Document Overview...
More informationVersion 11, JAN2017. Regulatory Document Approval Parameters for WebDCU TM POINT. People Document Collection REGULATORY REQUIREMENTS
Regulatory Approval Parameters for WebDCU TM Collection Person Role CV Study Drug Recipient, Secondary SC within document 5 yrs. from effective Required for all site personnel who are directly involved
More informationEdition. MONTEREY COUNTY BEHAVIORAL HEALTH MD User Guide
Edition 1 MONTEREY COUNTY BEHAVIORAL HEALTH MD User Guide i Table of Content OderConnect/InfoScriber Registration CH1 Pg.2 Sign In to MyAvatar CH2..Pg.10 Sync OrderConnect Password CH3.Pg.14 Client Look
More informationRequest for Feedback. Manizhe Payton, MPH. Director Office of Clinical Site Oversight Division of AIDS February 22, 2017
Request for Feedback Manizhe Payton, MPH Director Office of Clinical Site Oversight Division of AIDS February 22, 2017 Background European Medicines Agency (EMA) inspected 2 clinical research sites in
More informationSparta Systems TrackWise Solution
Systems Solution 21 CFR Part 11 and Annex 11 Assessment October 2017 Systems Solution Introduction The purpose of this document is to outline the roles and responsibilities for compliance with the FDA
More informationCompliance Matrix for 21 CFR Part 11: Electronic Records
Compliance Matrix for 21 CFR Part 11: Electronic Records Philip E. Plantz, PhD, Applications Manager David Kremer, Senior Software Engineer Application Note SL-AN-27 Revision B Provided By: Microtrac,
More informationTraining Guide for Practitioners
Training Guide for Practitioners Washington State Department of Health Washington State Prescription Monitoring Program July 2014 RxSentry is a proprietary system for prescription monitoring provided by
More informationInformation Security Policy
Information Security Policy Author: Responsible Lead Executive Director: Endorsing Body: Governance or Assurance Committee Alan Ashforth Colin Sloey Implementation Date: September 2010 Version Number:
More informationIRBManager Quick Start Guide INITIAL APPLICATION - OVERVIEW
Page 1 of 16 GENERAL INFORMATION IRBManager Quick Start Guide INITIAL APPLICATION - OVERVIEW Initial Application Types: The IRBManager initial application form (xform) is available for specific types of
More informationUser Guide 16-Mar-2018
16-Mar-2018 This document is freely distributable Identification Authors Name Organization Title TMF User Guide and Implementation Guide Sub-Team Version History Version Steering Committee Approval Date
More informationCompliance of Shimadzu Total Organic Carbon (TOC) Analyzer with FDA 21 CFR Part 11 Regulations on Electronic Records and Electronic Signatures
NT1D-1275 Compliance of Shimadzu Total Organic Carbon (TOC) Analyzer with FDA 21 CFR Part 11 Regulations on Electronic Records and Electronic Signatures TOC-Control L Ver.1 / LabSolutions DB/CS Ver.6 Part
More informationTraining Guide for Practitioners. Washington State Department of Health Washington State Prescription Monitoring Program
Training Guide for Practitioners Washington State Department of Health Washington State Prescription Monitoring Program April 2017 Training Guide for Practitioners Contents Contents 1 Document Overview...
More informationWhat is a Prescription Drug Monitoring Program?
What is a Prescription Drug Monitoring Program? A prescription drug monitoring program (PDMP) is a state program that collects controlled substance prescription records from dispensers (e.g., pharmacies)
More informationPrepared by. On behalf of The California HealthCare Foundation. Nov. 24, Sujansky & Associates, LLC 1
Guidelines for the Electronic Prescribing of Controlled Substances: Identity Proofing, Issuing Authentication Credentials, and Configuring Logical Access Controls Prepared by Sujansky & Associates, LLC
More informationSERVICE MANUAL MMCAP Return Goods Program For Outdated Rx, OTC and HBC Product Contract Number MMS28015
SERVICE MANUAL MMCAP Return Goods Program For Outdated Rx, OTC and HBC Product Contract Number MMS28015 RETURN GOODS PROGRAM SUMMARY CYCLE DATES Cycle dates are automatically scheduled every TWO MONTHS
More informationOnCore Enterprise Research. Subject Administration Full Study
OnCore Enterprise Research Subject Administration Full Study Principal Investigator Clinical Research Coordinator June 2017 P a g e 1 This page is intentionally blank. P a g e 2 Table of Contents What
More informationVaccine data collection tool Oct Functions, Indicators & Sub-Indicators
data collection tool Oct. 2011 A. National Regulatory System RS01: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function RS01.01: Legislation or and
More informationYOUR GUIDE TO I-STOP COMPLIANCE AND EPCS
YOUR GUIDE TO I-STOP COMPLIANCE AND EPCS Q: I prescribe medication in New York. Why does EPCS matter to me? A: Beginning March 2015, paper prescriptions will no longer be accepted. Beginning March 27,
More informationTraining Guide for Arkansas Practitioners and Pharmacists. Arkansas Department of Health Prescription Monitoring Program
Training Guide for Arkansas Practitioners and Pharmacists Arkansas Department of Health Prescription Monitoring Program May 2013 Contents Contents 1 Document Overview... 1 Purpose and Contents... 1 2 System
More informationSparta Systems Stratas Solution
Systems Solution 21 CFR Part 11 and Annex 11 Assessment October 2017 Systems Solution Introduction The purpose of this document is to outline the roles and responsibilities for compliance with the FDA
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: Protocol development SOP number: TM 010 SOP category: Trial Management Version number: 03 Version date: 16 December 2016 Effective date: 16 January 2017 Revision due date: 16 January
More informationTraining Guide for Wisconsin Practitioners and Pharmacists. Pharmacy Examining Board Wisconsin Department of Safety and Professional Services
Training Guide for Wisconsin Practitioners and Pharmacists Pharmacy Examining Board Wisconsin Department of Safety and Professional Services October 2013 Contents Contents 1 Document Overview... 1 Purpose
More informationDevelopment of your Company s Record Information System and Disaster Preparedness. The National Emergency Management Summit
Development of your Company s Record Information System and Disaster Preparedness The National Emergency Management Summit Thomas D. Anthony Frost Brown Todd LLC Attorneys at Law 201 E. Fifth Street Cincinnati,
More informationRPR CRITERIA AND FORMATS
RPR CRITERIA AND FORMATS PURPOSE This procedure establishes design criteria and standard formats for detailed procedures and records required for effective operations, communications and management of
More informationChromQuest 5.0. Tools to Aid in 21 CFR Part 11 Compliance. Introduction. General Overview. General Considerations
ChromQuest 5.0 Tools to Aid in 21 CFR Part 11 Compliance Introduction Thermo Scientific, Inc. is pleased to offer the ChromQuest chromatography data system (CDS) as a solution for chromatography labs seeking
More informationPRESCRIPTION MONITORING PROGRAM (PMP)
PRESCRIPTION MONITORING PROGRAM (PMP) DATA REPORTING MANUAL Effective Date: April 1, 2012 Contact Information: (505) 222-9830 larry.loring@state.nm.us 1 P a g e Table of Contents Reporting requirements
More informationData Integrity and the FDA AFDO Education Conference
Data Integrity and the FDA AFDO Education Conference June, 2018 OUR EXPERIENCE YOUR SUCCESS 1 Data Integrity What does it mean to you? 2 Data Integrity What does FDA say about data integrity No legal definition
More informationPOLICY AND PROCEDURES OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY. Procedures for Handling Requests for Proprietary Name Review.
POLICY AND PROCEDURES OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY Procedures for Handling Requests for Proprietary Name Review Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2 RESPONSIBILITIES AND PROCEDURES...3
More informationINSTRUCTIONS FOR RECIPIENTS OF EMORY UNIVERSITY MATERIAL
INSTRUCTIONS FOR RECIPIENTS OF EMORY UNIVERSITY MATERIAL Material Transfer Agreement for Government Agencies, Academic Institutions and Non- Profit Entities Please read these instructions carefully and
More informationSubject: University Information Technology Resource Security Policy: OUTDATED
Policy 1-18 Rev. 2 Date: September 7, 2006 Back to Index Subject: University Information Technology Resource Security Policy: I. PURPOSE II. University Information Technology Resources are at risk from
More informationRe: Docket ID No. DEA-316; Disposal of Controlled Substances; Notice of Proposed Rulemaking
VIA ELECTRONIC SUBMISSION: www.regulations.gov Drug Enforcement Administration Attention: DEA Office of Diversion Control (OD/DX) 8701 Morrissette Drive Springfield, VA 22152 Re: Docket ID No. DEA-316;
More informationVirginia State University Policies Manual. Title: Information Security Program Policy: 6110
Purpose Virginia State University (VSU) uses information to perform the business services and functions necessary to fulfill its mission. VSU information is contained in many different mediums including
More informationThe Data Protection Act 1998 Clare Hall Data Protection Policy
The Data Protection Act 1998 Clare Hall Data Protection Policy Introduction This document is a guide to the main requirements of the new Data Protection Act (DPA) that came into force on 24th October 2001.
More informationRI AND RF CRITERIA AND FORMATS
RI-42 RI AND RF CRITERIA AND FORMATS PURPOSE This procedure establishes design criteria and standard formats for detailed procedures and records required for effective operations, communications and management
More informationA guide to filling out Health Canada Exemption Applications
Page 1 of 16 A guide to filling out Health Canada Exemption Applications A controlled substance exemption is a document issued by Health Canada authorising you to possess a specific quantity of a controlled
More informationSOP Owner: Finance Last Reviewed/Update Date: 10/05/2015. Petty Cash Reimbursement on Grants Standard Operating Procedure
Petty Cash Reimbursement on Grants Standard Operating Procedure 1. Purpose WCMC is required by federal regulation to monitor and review any research related costs associated to Grants. All transactions
More informationSTANDARD OPERATING PROCEDURE SOP 815. Clinical Data Management System LOCKING AND UNLOCKING THE DATABASE. Joint Research Office
STANDARD OPERATING PROCEDURE SOP 815 Clinical Data Management System LOCKING AND UNLOCKING THE DATABASE Version 2.1 Version date 19/06/2017 Effective date 08/08/2017 Number of pages 6 Review date June
More informationUNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE
UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES University of Leicester (UoL)
More informationSelect Agents and Toxins Security Plan Template
Select Agents and Toxins Security Plan Template 7 CFR Part 331.11, 9 CFR Part 121.11, 42 CFR Part 73.11 Prepared by U.S. Department of Health and Human Services (HHS) Centers for Disease Control and Prevention
More informationGood Laboratory Practice GUIDELINES FOR THE ARCHIVING OF ELECTRONIC RAW DATA IN A GLP ENVIRONMENT. Release Date:
AGIT: Swiss Working Group on Information Technology in a GLP Environment Good Laboratory Practice GUIDELINES FOR THE ARCHIVING OF ELECTRONIC RAW DATA IN A GLP ENVIRONMENT Release Date: 31.01.2018 Version:
More informationBioInformatics A Roadmap To Success. Data Management Plans. Wes Rountree Associate Director of Data Management Family Health International
BioInformatics A Roadmap To Success Data Management Plans Wes Rountree Associate Director of Data Management Family Health International What is a Data Management Plan? A document that describes how clinical
More informationStep By Step Registration Process
The Florida Prescription Drug Monitoring Program, known as E FORCSE (Electronic Florida Online Reporting of Controlled Substance Evaluation Program), was created by the 2009 Florida Legislature in an initiative
More informationIRT & ecoa: The Good, The Bad & The Ugly YPrime, inc. All Rights Reserved
What we would like to share: Overview of the concept of IRT and ecoa integration Benefits and challenges of scanning in an integrated system Using an integrated system for drug accountability and reconciliation
More informationPolicy and Procedure: SDM Guidance for HIPAA Business Associates
Policy and Procedure: SDM Guidance for HIPAA Business (Adapted from UPMC s Guidance for Business at http://www.upmc.com/aboutupmc/supplychainmanagement/documents/guidanceforbusinessassociates.pdf) Effective:
More informationDeployment Prescription Program (DPP)
Defense Health Agency Deployment Prescription Program (DPP) Overview for the Pre-Deployment Site January 2015 1 DHA Pharmacy Analytics Support Section (PASS) Primary point of contact for all questions
More informationElectronic Data Capture (EDC) Systems and Part 11 Compliance
Electronic Data Capture (EDC) Systems and Part 11 Compliance Office of New Animal Drug Evaluation Center for Veterinary Medicine Society of Quality Assurance Gaylord Hotel, Washington DC March 28, 2017
More informationCTI BioPharma Privacy Notice
CTI BioPharma Privacy Notice Effective: 29 November 2018 Introduction and Scope CTI BioPharma Corp. ( CTI, our, us ) takes the protection of your personal data very seriously. This Privacy Notice (this
More informationResearch Data Use Agreement (RDUA)
Page 1 of 5 Research Data Use Agreement (RDUA) I. Introduction and Definitions 1. Cortisol Quantification Investigation (CQI): Prospective, Observational Study Comparing Free versus Total Serum Cortisol
More informationAIDS CLINICAL TRIALS GROUP (ACTG)
AIDS CLINICAL TRIALS GROUP (ACTG) Network Standard Operating Procedure Title Specimen Archiving Approval Process for ACTG Non-priority Protocols SOP number ACTG-145 Effective: 10/15/2018 Version 7.0 Last
More informationDEA In a Community Pharmacy Part 2 By Bruce R. Siecker, Ph.D., R.Ph.
DEA In a Community Pharmacy Part 2 By Bruce R. Siecker, Ph.D., R.Ph. Bruce Siecker is president of Paradigm Research & Advisory Services, Inc. based in Stone Ridge, Virginia. He trains, writes, consults,
More informationeprmc User Manual For Investigators and Research Staff
eprmc User Manual For Investigators and Research Staff Table of Contents How to Get an Account... 3 Logging In... 3 Overview of the eprmc Database... 4 Searching for a Protocol... 5 Adding a New Protocol...
More informationDF/HCC Operations for Human Research Subject Registration Procedures
1. BACKGROUND: This document outlines the appropriate procedures for subject registration and other registration situations that may arise. To quickly locate a specific topic, please use the hyperlinks
More informationIntroduction. Lesson 1 Access and Basic Navigation
Introduction Hello and Welcome to PRA s etmf Basics for External Users This tutorial is designed to provide you with a basic overview of PRA s etmf 3 System that you will be using to access your Trial
More informationUniform Biological Material Transfer Agreement SAMPLE
Uniform Biological Material Transfer Agreement The purpose of this agreement is to provide a record of the biological material transfer and to memorialize the agreement between the PROVIDER, PROVIDER S
More informationISSP Network Security Plan
ISSP-000 - Network Security Plan 1 CONTENTS 2 INTRODUCTION (Purpose and Intent)... 1 3 SCOPE... 2 4 STANDARD PROVISIONS... 2 5 STATEMENT OF PROCEDURES... 3 5.1 Network Control... 3 5.2 DHCP Services...
More informationRed Flags/Identity Theft Prevention Policy: Purpose
Red Flags/Identity Theft Prevention Policy: 200.3 Purpose Employees and students depend on Morehouse College ( Morehouse ) to properly protect their personal non-public information, which is gathered and
More informationRecommendations for Implementing an Information Security Framework for Life Science Organizations
Recommendations for Implementing an Information Security Framework for Life Science Organizations Introduction Doug Shaw CISA, CRISC Director of CSV & IT Compliance Azzur Consulting Agenda Why is information
More information